Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SU101 Plus Mitoxantrone/Prednisone in Hormone-Refractory Prostate Cancer
NCT00004071Phase 3Completed
- Sponsor
- Pfizer
- Start
- Aug 1999
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of leflunomide in prostate cancer (PCa) (2 arms), sponsored by Pfizer. Primary endpoint: Percentage One Year Survival Rate at 1 year. Started Aug 1999; status: completed.
02
Drugs
leflunomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00004071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004071.